-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Eli Lilly announced that it will spend up to $1 billion to acquire the biotechnology company Protomer Technologies
Protomer was founded in 2015 and is headquartered in California, USA.
Since the 1970s, diabetes researchers have been seeking to develop a glucose-responsive insulin, but it has been limited due to its unsatisfactory speed and sensitivity
Eli Lilly and Novo Nordisk, as the world's leading diabetes drug developers, restrict each other
However, Eli Lilly has taken the lead in developing a next-generation non-insulin injection called tirzepatide, which is about to undergo regulatory review
The glucose-responsive insulin developed by Eli Lilly and Novo Nordisk can solve the clinical needs of the diabetes market
Researchers believe that when the patient's glucose level rises, glucose-responsive insulin can immediately activate insulin to take effect, providing patients with better disease control effects and reducing the risk of hypoglycemia
The two companies did not disclose the specific details of the advance payment and milestone payment
Reference source:
1.
2.